Imperatorin-Loaded RH60/mPEG–PLLA Micelles for Reversing Tamoxifen Resistance in Breast Cancer
Source abstract
Abstract
Imperatorin (IMP) has demonstrated potential in reversing drug resistance in various tumor cells; however, its limited clinical application and development are attributed to its poor water solubility and low bioavailability. The current work is intended to enhance the oral bioavailability of IMP and its efficacy in overcoming tamoxifen (TAM) resistance in breast cancer cells. We employed mPEG–PLLA and Cremophor RH60 (RH60) to prepare imperatorin nanomicelles (IMP-RH60/mPEG–PLLA). The freeze-dried powder of IMP-RH60/mPEG–PLLA demonstrated a porous structure, and upon reconstitution, the resulting solution exhibited clarity and transparency. The particle size was measured to be 25.48 ± 0.92 nm, with a zeta potential of −5.50 ± 1.06 mV. The encapsulation efficiency was determined to be 85.78 ± 0.84%, while the drug loading was found to be 2.66 ± 0.03%. In comparison to the active pharmaceutical ingredients (APIs) of IMP, IMP-RH60/mPEG–PLLA exhibited a significant increase in in vitro release, improved bioavailability in rats, and enhanced uptake by MCF-7/TAM cells. The coadministration of IMP-RH60/mPEG–PLLA and TAM effectively inhibited the proliferation, colony formation, migration, and invasion of MCF-7/TAM cells. This outcome could potentially be attributed to the downregulation of GST-π and MDR1 drug resistance genes, consequently augmenting the susceptibility of MCF-7/TAM cells to TAM. An experimental model of BALB/c nude xenograft, consisting of human breast cancer cells resistant to tamoxifen (TAM), was established in order to assess the potential in vivo reversal of TAM resistance through the use of IMP-RH60/mPEG–PLLA. The growth of xenografts was inhibited by IMP-RH60/mPEG–PLLA, and it induced apoptosis in tumor tissues through the downregulation of K i -67, GST-π, and MDR1 gene expression. The findings indicated that the utilization of IMP-RH60/mPEG–PLLA micelles resulted in an enhancement of IMP’s bioavailability and its efficacy in overcoming TAM resistance.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer therapeutics and mechanisms · Cancer Treatment and Pharmacology · Estrogen and related hormone effects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004, China
School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang 330013, China
Funding
National Natural Science Foundation of China · Key Laboratory of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Chinese Medicine · Natural Science Foundation of Jiangxi University of TCM
References (53)
Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1007/s00109-021-02136-510.1007/s00109-021-02136-5 ↗
3. 10.1186/s13045-018-0577-510.1186/s13045-018-0577-5 ↗
4. 10.3390/biom1207091610.3390/biom12070916 ↗
5. 10.1111/cns.1374810.1111/cns.13748 ↗
6. 10.3390/antibiotics1009107510.3390/antibiotics10091075 ↗
7. 10.3390/antiox1003036210.3390/antiox10030362 ↗
8. 10.1016/j.jep.2020.11373610.1016/j.jep.2020.113736 ↗
9. 10.1016/j.biopha.2019.10940110.1016/j.biopha.2019.109401 ↗
10. 10.1016/j.jep.2020.11294510.1016/j.jep.2020.112945 ↗
11. 10.1186/s12935-021-02397-710.1186/s12935-021-02397-7 ↗
12. 10.1155/2020/802683810.1155/2020/8026838 ↗
13. 10.1007/s13277-015-3591-z10.1007/s13277-015-3591-z ↗
14. 10.4196/kjpp.2022.26.3.14510.4196/kjpp.2022.26.3.145 ↗
15. 10.1080/10717544.2020.171824510.1080/10717544.2020.1718245 ↗
16. 10.3390/molecules2615448110.3390/molecules26154481 ↗
17. 10.2147/IJN.S17369110.2147/IJN.S173691 ↗
18. 10.1080/10717544.2018.145892310.1080/10717544.2018.1458923 ↗
19. 10.1016/j.carbpol.2014.12.08410.1016/j.carbpol.2014.12.084 ↗
20. 10.1080/13880209.2020.174216710.1080/13880209.2020.1742167 ↗
21. 10.3389/fcell.2021.79700510.3389/fcell.2021.797005 ↗
22. 10.3389/fphar.2019.0072210.3389/fphar.2019.00722 ↗
23. 10.3389/fphar.2021.65330610.3389/fphar.2021.653306 ↗
24. 10.3892/mmr.2020.1121110.3892/mmr.2020.11211 ↗
25. 10.3390/cells1119309410.3390/cells11193094 ↗
26. 10.1002/cam4.276410.1002/cam4.2764 ↗
27. 10.3389/fbioe.2021.78732010.3389/fbioe.2021.787320 ↗
28. 10.1002/jcp.2740210.1002/jcp.27402 ↗
29. Tang X. L. · J. Chinese Journal of Hospital Pharmacy. · 2021 · 41 · 1293
30. 10.1007/s00109-021-02047-510.1007/s00109-021-02047-5 ↗
31. 10.1002/advs.20200092510.1002/advs.202000925 ↗
32. 10.1016/j.jep.2017.03.03310.1016/j.jep.2017.03.033 ↗
33. Li S. N. · Chin. Tradit. Herb. Drugs · 2011 · 42 · 96
34. 10.1016/j.biocel.2015.07.01410.1016/j.biocel.2015.07.014 ↗
35. 10.1016/j.soc.2017.08.00510.1016/j.soc.2017.08.005 ↗
36. 10.1038/s41467-018-03951-010.1038/s41467-018-03951-0 ↗
37. 10.2147/CMAR.S22641010.2147/CMAR.S226410 ↗
38. 10.1002/jcp.2962910.1002/jcp.29629 ↗
39. 10.2147/IJN.S33540510.2147/IJN.S335405 ↗
40. 10.2147/IJN.S35253810.2147/IJN.S352538 ↗
41. 10.1002/kjm2.1211010.1002/kjm2.12110 ↗
42. 10.2147/IJN.S27408310.2147/IJN.S274083 ↗
43. 10.1080/10717544.2021.190575010.1080/10717544.2021.1905750 ↗
44. 10.2147/ijn.s22457910.2147/ijn.s224579 ↗
45. 10.1038/s41568-018-0005-810.1038/s41568-018-0005-8 ↗
46. 10.1002/cam4.576810.1002/cam4.5768 ↗
47. 10.1016/j.cbi.2021.10945010.1016/j.cbi.2021.109450 ↗
48. 10.3390/pharmaceutics1406126410.3390/pharmaceutics14061264 ↗
49. 10.1038/bjc.2017.19910.1038/bjc.2017.199 ↗
50. 10.3892/ol.2019.1031510.3892/ol.2019.10315 ↗
51. 10.2147/DDDT.S16983310.2147/DDDT.S169833 ↗
52. 10.1073/pnas.202650711810.1073/pnas.2026507118 ↗
53. 10.1002/cam4.372810.1002/cam4.3728 ↗